257 related articles for article (PubMed ID: 18480690)
1. Concentration-response relationship for fluvoxamine using remission as an endpoint: a receiver operating characteristics curve analysis in major depression.
Suzuki Y; Fukui N; Sawamura K; Sugai T; Watanabe J; Ono S; Inoue Y; Ozdemir V; Someya T
J Clin Psychopharmacol; 2008 Jun; 28(3):325-8. PubMed ID: 18480690
[TBL] [Abstract][Full Text] [Related]
2. Predictors of antidepressant response to fluvoxamine obtained using the three-factor structures of the Montgomery and Asberg Depression Rating Scale for major depressive disorders in Japanese patients.
Higuchi H; Sato K; Yoshida K; Takahashi H; Kamata M; Otani K; Yamaguchi N
Psychiatry Clin Neurosci; 2008 Jun; 62(3):301-6. PubMed ID: 18588590
[TBL] [Abstract][Full Text] [Related]
3. A case with occurring adverse effects when cross-over titration from fluvoxamine to paroxetine associated with increasing the plasma fluvoxamine level in major depressive disorder.
Hori H; Yoshimura R; Ueda N; Ikenouchi-Sugita A; Umene-Nakano W; Nakamura J
World J Biol Psychiatry; 2009; 10(4 Pt 2):620-2. PubMed ID: 18609433
[TBL] [Abstract][Full Text] [Related]
4. Serum concentrations of fluvoxamine and clinical effects. A prospective open clinical trial.
Härtter S; Wetzel H; Hammes E; Torkzadeh M; Hiemke C
Pharmacopsychiatry; 1998 Sep; 31(5):199-200. PubMed ID: 9832352
[TBL] [Abstract][Full Text] [Related]
5. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression.
Henkel V; Seemüller F; Obermeier M; Adli M; Bauer M; Mundt C; Brieger P; Laux G; Bender W; Heuser I; Zeiler J; Gaebel W; Mayr A; Möller HJ; Riedel M
J Affect Disord; 2009 Jun; 115(3):439-49. PubMed ID: 19027961
[TBL] [Abstract][Full Text] [Related]
6. Suitable dose and duration of fluvoxamine administration to treat depression.
Morishita S; Arita S
Psychiatry Clin Neurosci; 2003 Apr; 57(2):177-81. PubMed ID: 12667164
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic efficacy assessment of weak variable magnetic fields with low value of induction in patients with drug-resistant depression.
Sobiś J; Jarzab M; Hese RT; Sieroń A; Zyss T; Gorczyca P; Gierlotka Z; Pudlo R; Matysiakiewicz J
J Affect Disord; 2010 Jun; 123(1-3):321-6. PubMed ID: 19896204
[TBL] [Abstract][Full Text] [Related]
8. A comparative study of the efficacy and safety profiles between fluvoxamine and nortriptyline in Japanese patients with major depression.
Otsubo T; Akimoto Y; Yamada H; Koda R; Aoyama H; Tanaka K; Mimura M; Nakagome K; Kamijima K
Pharmacopsychiatry; 2005 Jan; 38(1):30-5. PubMed ID: 15706464
[TBL] [Abstract][Full Text] [Related]
9. Orphan nuclear receptor Rev-erb alpha gene (NR1D1) and fluvoxamine response in major depressive disorder in the Japanese population.
Kishi T; Kitajima T; Ikeda M; Yamanouchi Y; Kinoshita Y; Kawashima K; Okochi T; Ozaki N; Iwata N
Neuropsychobiology; 2009; 59(4):234-8. PubMed ID: 19571598
[TBL] [Abstract][Full Text] [Related]
10. Fast onset: an open study of the treatment of major depressive disorder with nefazodone and pindolol combination therapy.
Bakish D; Hooper CL; Thornton MD; Wiens A; Miller CA; Thibaudeau CA
Int Clin Psychopharmacol; 1997 Mar; 12(2):91-7. PubMed ID: 9219044
[TBL] [Abstract][Full Text] [Related]
11. [Maprotiline versus fluvoxamine: comparison of their effects on the hypothalamo-hypophyseal-thyroid axis].
De Mendonça Lima CA; Vandel S; Bonin B; Bechtel P; Carron R
Encephale; 1997; 23(1):48-55. PubMed ID: 9172968
[TBL] [Abstract][Full Text] [Related]
12. Hopelessness as a predictor of non-response to fluoxetine in major depressive disorder.
Papakostas GI; Petersen T; Homberger CH; Green CH; Smith J; Alpert JE; Fava M
Ann Clin Psychiatry; 2007; 19(1):5-8. PubMed ID: 17453655
[TBL] [Abstract][Full Text] [Related]
13. Genetic association analysis of functional polymorphisms in neuronal nitric oxide synthase 1 gene (NOS1) and mood disorders and fluvoxamine response in major depressive disorder in the Japanese population.
Okumura T; Kishi T; Okochi T; Ikeda M; Kitajima T; Yamanouchi Y; Kinoshita Y; Kawashima K; Tsunoka T; Inada T; Ozaki N; Iwata N
Neuropsychobiology; 2010; 61(2):57-63. PubMed ID: 20016223
[TBL] [Abstract][Full Text] [Related]
14. Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder.
Papakostas GI; McGrath P; Stewart J; Charles D; Chen Y; Mischoulon D; Dording C; Fava M
Psychiatry Res; 2008 Oct; 161(1):116-20. PubMed ID: 18755514
[TBL] [Abstract][Full Text] [Related]
15. Sertraline treatment of patients with major depressive disorder who failed initial treatment with paroxetine or fluvoxamine.
Inoue T; Honda M; Kawamura K; Tsuchiya K; Suzuki T; Ito K; Matsubara R; Shinohara K; Ishikane T; Sasaki K; Boku S; Fujisawa D; Ono Y; Koyama T
Prog Neuropsychopharmacol Biol Psychiatry; 2012 Aug; 38(2):223-7. PubMed ID: 22504727
[TBL] [Abstract][Full Text] [Related]
16. Effects of imipramine, fluvoxamine and depressive mood on autonomic cardiac functioning in major depressive disorder.
Volkers AC; Tulen JH; van den Broek WW; Bruyn JA; Passchier J; Pepplinkhuizen L
Pharmacopsychiatry; 2004 Jan; 37(1):18-25. PubMed ID: 14750044
[TBL] [Abstract][Full Text] [Related]
17. The influence of lithium on fluvoxamine therapeutic efficacy and pharmacokinetics in depressed patients on combined fluvoxamine-lithium therapy.
Miljković BR; Pokrajac M; Timotijević I; Varagić V
Int Clin Psychopharmacol; 1997 Jul; 12(4):207-12. PubMed ID: 9347381
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder.
Leuchter AF; Cook IA; Gilmer WS; Marangell LB; Burgoyne KS; Howland RH; Trivedi MH; Zisook S; Jain R; Fava M; Iosifescu D; Greenwald S
Psychiatry Res; 2009 Sep; 169(2):132-8. PubMed ID: 19709754
[TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacokinetics of fluvoxamine: applications to dosage regimen design.
DeVane CL; Gill HS
J Clin Psychiatry; 1997; 58 Suppl 5():7-14. PubMed ID: 9184622
[TBL] [Abstract][Full Text] [Related]
20. Electrocardiographic findings during extended clinical trials of fluvoxamine in depression: one years experience.
Hochberg HM; Kanter D; Houser VP
Pharmacopsychiatry; 1995 Nov; 28(6):253-6. PubMed ID: 8773292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
